BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-635@pharmaconomics
DTSTAMP:20260707T034513Z
DTSTART;VALUE=DATE:20260603
DTEND;VALUE=DATE:20260604
SUMMARY:ADCT Phase 3 — ZYNLONTA
DESCRIPTION:Phase 3 trial results for ZYNLONTA in relapsed or refractory diffuse large B-cell lymphoma are due Jun 3\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_9901.htm\n\nTrack it: https://www.pharmaconomics.com/e/635
URL:https://www.pharmaconomics.com/e/635
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ADCT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR